Recombinant MVA expressing secreted glycoprotein D of BoHV-1 induces systemic and mucosal immunity in animal models
| Autor: | María Florencia Ferrer, Gabriela Calamante, Osvaldo Zabal, Alejandro Rafael Valera, María Paula Del Médico Zajac, Flavia Zanetti |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Male
Cholera Toxin Time Factors Immunology Genetic Vectors Vaccinia virus Herpesvirus Vaccines Biology Antibodies Viral law.invention Rodent Diseases Mice Viral Proteins Adjuvants Immunologic law Virology Glycoprotein D Animals Pathogen Mucosal immunity Administration Intranasal Drug Carriers Mice Inbred BALB C Vaccines Synthetic Herpesviridae Infections Immunoglobulin A Virus Shedding Disease Models Animal Nasal Mucosa Immunoglobulin G Recombinant DNA Molecular Medicine Female Bronchoalveolar Lavage Fluid |
| Zdroj: | Viral immunology. 24(4) |
| ISSN: | 1557-8976 |
| Popis: | Bovine herpesvirus-1 (BoHV-1) infection is distributed worldwide and the development of new tools to fight against this pathogen has become extremely important. In this work a recombinant modified vaccinia virus Ankara (MVA) vector expressing the secreted version of glycoprotein D, MVA-gDs, was obtained and evaluated as a candidate vaccine. First, the correct expression, antigenicity, and N-glycosylation of glycoprotein D were confirmed by molecular techniques. Then MVA-gDs was used as parenteral immunogen in BALB/C mice in which a specific anti-gD humoral immune response was induced and maintained for 7 mo. Two doses of MVA-gDs supplemented with cholera toxin delivered by intranasal immunization induced IgA anti-gD humoral immune responses in nasal and bronchopulmonary washes, as well as IgG anti-gD antibodies in serum samples. In order to evaluate the protection conferred by MVA-gDs immunization, a rabbit BoHV-1 challenge assay was performed. A shorter viral excretion period and a reduction in the number of animals shedding BoHV-1 was observed in the group immunized with recombinant MVA-gDs. In conclusion our data encourage further studies to evaluate MVA-gDs, alone or combined with other immunogens, as a candidate vaccine for BoHV-1. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|